Literature DB >> 25036277

Gallstones in pediatric hematopoietic cell transplant survivors with up to 40 years of follow-up.

Paul A Hoffmeister1, Barry E Storer, George B McDonald, K Scott Baker.   

Abstract

PURPOSE: To determine risk factors for the development of gallstones and the prevalence of related cholecystectomy in children following hematopoietic cell transplantation (HCT). PATIENTS AND METHODS: A retrospective chart review of 1343 patients aged below 18 years old who survived at least 1 year after HCT from 1969 to 2011 was performed. Multivariate Cox regression models were used to estimate the hazard ratio (HR) of risk factors associated with gallstones.
RESULTS: Gallstones developed in 91 patients, a median of 3.5 (range, 0.1 to 30.9) years after HCT at 16.3 (range, 0.8 to 44.2) years of age, with a 40-year cumulative incidence of 11%. At initial diagnosis, 61 (67%) patients were symptomatic and 30 (23%) had incidental gallstones. Risk factors associated with gallstones included autologous transplant (HR=2.7, P=0.02), unrelated donor (HR=2.0, P=0.05), grade 3 to 4 acute graft-versus-host disease (GVHD) (HR=2.2, P=0.03), chronic GVHD (HR=2.0, P=0.05), second transplant (HR=2.3, P=0.03), diabetes (HR=2.2, P=0.05), and estrogen therapy (HR=1.8, P=0.03). Fifty-six patients underwent cholecystectomy. The prevalence of cholecystectomy among 853 surviving patients was 5.2%.
CONCLUSIONS: Childhood HCT patients have an increased risk of developing gallstones.

Entities:  

Mesh:

Year:  2014        PMID: 25036277      PMCID: PMC4429603          DOI: 10.1097/MPH.0000000000000213

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  30 in total

1.  Chemical composition of gallbladder sludge in patients after marrow transplantation.

Authors:  C W Ko; C Murakami; J H Sekijima; M H Kim; G B McDonald; S P Lee
Journal:  Am J Gastroenterol       Date:  1996-06       Impact factor: 10.864

Review 2.  Bone-marrow transplantation (first of two parts).

Authors:  E Thomas; R Storb; R A Clift; A Fefer; F L Johnson; P E Neiman; K G Lerner; H Glucksberg; C D Buckner
Journal:  N Engl J Med       Date:  1975-04-17       Impact factor: 91.245

3.  Management of cholelithiasis in pediatric patients who undergo bone marrow transplantation.

Authors:  S D Safford; K M Safford; P Martin; H Rice; J Kurtzberg; M A Skinner
Journal:  J Pediatr Surg       Date:  2001-01       Impact factor: 2.545

4.  Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial.

Authors:  H J Deeg; D Lin; W Leisenring; M Boeckh; C Anasetti; F R Appelbaum; T R Chauncey; K Doney; M Flowers; P Martin; R Nash; G Schoch; K M Sullivan; R P Witherspoon; R Storb
Journal:  Blood       Date:  1997-05-15       Impact factor: 22.113

5.  Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children.

Authors:  Ann E Woolfrey; Claudio Anasetti; Barry Storer; Kristine Doney; Laurie A Milner; Eric L Sievers; Paul Carpenter; Paul Martin; Effie Petersdorf; Frederick R Appelbaum; John A Hansen; Jean E Sanders
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

6.  Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.

Authors:  H Joachim Deeg; Barry Storer; John T Slattery; Claudio Anasetti; Kristine C Doney; John A Hansen; Hans-Peter Kiem; Paul J Martin; Effie Petersdorf; Jerald P Radich; Jean E Sanders; Howard M Shulman; Edus H Warren; Robert P Witherspoon; Eileen M Bryant; Thomas R Chauncey; Lisa Getzendaner; Rainer Storb; Frederick R Appelbaum
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

7.  Diabetes mellitus in long-term survivors of pediatric hematopoietic cell transplantation.

Authors:  Paul A Hoffmeister; Barry E Storer; Jean E Sanders
Journal:  J Pediatr Hematol Oncol       Date:  2004-02       Impact factor: 1.289

8.  Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study.

Authors:  K Scott Baker; James G Gurney; Kirsten K Ness; Ravi Bhatia; Stephen J Forman; Liton Francisco; Philip B McGlave; Leslie L Robison; David S Snyder; Daniel J Weisdorf; Smita Bhatia
Journal:  Blood       Date:  2004-06-01       Impact factor: 22.113

9.  Outcome of allogeneic bone marrow transplantation for children with advanced acute myeloid leukemia.

Authors:  E R Nemecek; T A Gooley; A E Woolfrey; P A Carpenter; D C Matthews; J E Sanders
Journal:  Bone Marrow Transplant       Date:  2004-11       Impact factor: 5.483

10.  Biliary diseases in heart transplanted patients: a comparison between cyclosporine A versus tacrolimus-based immunosuppression.

Authors:  J Stief; H U Stempfle; M Götzberger; P Uberfuhr; M Köpple; P Lehnert; C Kaiser; Uwe Schiemann
Journal:  Eur J Med Res       Date:  2009-05-14       Impact factor: 2.175

View more
  1 in total

1.  Complex profile of multiple hepatobiliary and gastrointestinal complications after hematopoietic stem cell transplantation in a child with Nijmegen breakage syndrome.

Authors:  Przemysław Gałązka; Krzysztof Czyżewski; Anna Szaflarska-Popławska; Robert Dębski; Anna Krenska; Jan Styczyński
Journal:  Cent Eur J Immunol       Date:  2019-09-30       Impact factor: 2.085

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.